Is there a role for IGF‐1 in the development of second primary cancers?
Abstract Cancer survival rates are increasing, and as a result, more cancer survivors are exposed to the risk of developing a second primary cancer (SPC). It has been hypothesized that one of the underlying mechanisms for this risk could be mediated by variations in insulin‐like growth factor‐1 (IGF...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-11-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.871 |
| _version_ | 1817983146535157760 |
|---|---|
| author | Thurkaa Shanmugalingam Cecilia Bosco Anne J. Ridley Mieke Van Hemelrijck |
| author_facet | Thurkaa Shanmugalingam Cecilia Bosco Anne J. Ridley Mieke Van Hemelrijck |
| author_sort | Thurkaa Shanmugalingam |
| collection | DOAJ |
| description | Abstract Cancer survival rates are increasing, and as a result, more cancer survivors are exposed to the risk of developing a second primary cancer (SPC). It has been hypothesized that one of the underlying mechanisms for this risk could be mediated by variations in insulin‐like growth factor‐1 (IGF‐1). This review summarizes the current epidemiological evidence to identify whether IGF‐1 plays a role in the development of SPCs. IGF‐1 is known to promote cancer development by inhibiting apoptosis and stimulating cell proliferation. Epidemiological studies have reported a positive association between circulating IGF‐1 levels and various primary cancers, such as breast, colorectal, and prostate cancer. The role of IGF‐1 in increasing SPC risk has been explored less. Nonetheless, several experimental studies have observed a deregulation of the IGF‐1 pathway, which may explain the association between IGF‐1 and SPCs. Thus, measuring serum IGF‐1 may serve as a useful marker in assessing the risk of SPCs, and therefore, more translational experimental and epidemiological studies are needed to further disentangle the role of IGF‐1 in the development of specific SPCs. |
| first_indexed | 2024-04-13T23:29:47Z |
| format | Article |
| id | doaj.art-6532cb6caddd487cb122c583b6dc3c41 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-13T23:29:47Z |
| publishDate | 2016-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-6532cb6caddd487cb122c583b6dc3c412022-12-22T02:24:57ZengWileyCancer Medicine2045-76342016-11-015113353336710.1002/cam4.871Is there a role for IGF‐1 in the development of second primary cancers?Thurkaa Shanmugalingam0Cecilia Bosco1Anne J. Ridley2Mieke Van Hemelrijck3Division of Cancer Studies Cancer Epidemiology Group King's College London London United KingdomDivision of Cancer Studies Cancer Epidemiology Group King's College London London United KingdomRandall Division of Cell and Molecular Biophysics King's College London London United KingdomDivision of Cancer Studies Cancer Epidemiology Group King's College London London United KingdomAbstract Cancer survival rates are increasing, and as a result, more cancer survivors are exposed to the risk of developing a second primary cancer (SPC). It has been hypothesized that one of the underlying mechanisms for this risk could be mediated by variations in insulin‐like growth factor‐1 (IGF‐1). This review summarizes the current epidemiological evidence to identify whether IGF‐1 plays a role in the development of SPCs. IGF‐1 is known to promote cancer development by inhibiting apoptosis and stimulating cell proliferation. Epidemiological studies have reported a positive association between circulating IGF‐1 levels and various primary cancers, such as breast, colorectal, and prostate cancer. The role of IGF‐1 in increasing SPC risk has been explored less. Nonetheless, several experimental studies have observed a deregulation of the IGF‐1 pathway, which may explain the association between IGF‐1 and SPCs. Thus, measuring serum IGF‐1 may serve as a useful marker in assessing the risk of SPCs, and therefore, more translational experimental and epidemiological studies are needed to further disentangle the role of IGF‐1 in the development of specific SPCs.https://doi.org/10.1002/cam4.871Breast cancercolorectal cancerIGF‐1lung cancerprostate cancersecond primary cancer |
| spellingShingle | Thurkaa Shanmugalingam Cecilia Bosco Anne J. Ridley Mieke Van Hemelrijck Is there a role for IGF‐1 in the development of second primary cancers? Cancer Medicine Breast cancer colorectal cancer IGF‐1 lung cancer prostate cancer second primary cancer |
| title | Is there a role for IGF‐1 in the development of second primary cancers? |
| title_full | Is there a role for IGF‐1 in the development of second primary cancers? |
| title_fullStr | Is there a role for IGF‐1 in the development of second primary cancers? |
| title_full_unstemmed | Is there a role for IGF‐1 in the development of second primary cancers? |
| title_short | Is there a role for IGF‐1 in the development of second primary cancers? |
| title_sort | is there a role for igf 1 in the development of second primary cancers |
| topic | Breast cancer colorectal cancer IGF‐1 lung cancer prostate cancer second primary cancer |
| url | https://doi.org/10.1002/cam4.871 |
| work_keys_str_mv | AT thurkaashanmugalingam istherearoleforigf1inthedevelopmentofsecondprimarycancers AT ceciliabosco istherearoleforigf1inthedevelopmentofsecondprimarycancers AT annejridley istherearoleforigf1inthedevelopmentofsecondprimarycancers AT miekevanhemelrijck istherearoleforigf1inthedevelopmentofsecondprimarycancers |